BSE · 530125
Samrat Pharmachem Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹287 Cr with net profit ₹7 Cr — a 2.48% net margin, versus 0.76% the period before.
Shareholding
As of 2026-06-30
- Promoter49.09%
- Public47.67%
- FII3.24%
6,330 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.87× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #21 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,07,995 Cr | 276.76 | 12.39 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,475 Cr | 200.98 | 16.01 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,636 Cr | 68.22 | 13.15 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,317 Cr | 127.37 | 2.14 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,768 Cr | 68.23 | 2.43 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,509 Cr | 34.4 | 4.47 | 12.98% | 11.5% |
| Hikal Limited | ₹2,676 Cr | 185.46 | 2.24 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,234 Cr | 246.74 | 9.13 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,026 Cr | 42.12 | 6.16 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,370 Cr | 69.88 | 3.29 | 17.67% | 13.66% |
| Samrat Pharmachem Ltd.(this company) | ₹78 Cr | — | 1.14 | -4.86% | -1.15% |
AI analysis
AI-generated · google/gemini-2.5-flashSamrat Pharmachem Ltd. (SAMRATPHARMACHEMLTD) has a market capitalization of Rs 81 Cr. The company reported revenue of Rs 286.83 Cr and a profit margin of -114.6%. The debt-to-equity ratio stands at 0.13.
Positives
- +The debt-to-equity ratio is 0.13.
- +Promoter holding of 49.0911% as of June 30, 2026, reflects a significant stake.
- +No promoter shares are reported as pledged.
Negatives
- −The company reported a profit margin of -114.6%.
- −Return on Equity (ROE) is negative at -485.8%.
- −Return on Capital Employed (ROCE) is negative at -2.5679%.
- −Net profit has been negative for the last four reported quarters, reaching -Rs 2.04 Cr in March 2026.
- −Quarterly EBITDA has turned negative, recorded at -Rs 1.74 Cr in March 2026.
Financial Performance
Annual revenue for Samrat Pharmachem Ltd. was Rs 286.83 Cr for the period ending March 2025. Net profit for the same period was Rs 7.1122 Cr. The company's EPS was Rs 23.02 in March 2025, an increase from Rs 7 in March 2024. Quarterly revenue decreased from Rs 78.87 Cr in September 2025 to Rs 71.77 Cr in March 2026.
Profitability & Returns
The company's profit margin was -114.6%. Return on Equity (ROE) was -485.8% and Return on Capital Employed (ROCE) was -2.5679%. The Earnings Per Share (EPS) for March 2025 was Rs 23.02. Quarterly net profit has been negative, with the latest recorded at -Rs 2.04 Cr in March 2026.
Balance Sheet
Samrat Pharmachem Ltd. has a book value of Rs 220.67. The debt-to-equity ratio is 0.13. No dividend yield has been reported for the company.
Ownership & Pledges
As of June 30, 2026, promoter holding in Samrat Pharmachem Ltd. was 49.0911%. Public shareholding was 47.6723% and FIIs held 3.2366%. There are no reported promoter pledges.
Quarterly Performance
Quarterly results show a decline in net profit, moving from Rs 2.78 Cr in December 2024 to -Rs 2.04 Cr in March 2026. EBITDA also decreased from Rs 4.01 Cr in December 2024 to -Rs 1.74 Cr in March 2026. Revenue has shown fluctuations, reaching Rs 78.87 Cr in September 2025 before declining to Rs 71.77 Cr in March 2026.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.